Peptide-targeted radionuclide therapy for melanoma

Critical Reviews in Oncology/Hematology

Volumn 67, Issue 3, 2008, Pages 213-228

  Miao, Yubin ^a,b,c   Quinn, Thomas P ^d,e  

^a UNIVERSITY OF NEW MEXICO   (United States)

^b UNIVERSITY OF NEW MEXICO   (United States)

^c UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^d University of Missouri   (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Melanoma; Peptide targeted; Radionuclide therapy

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; ALPHA INTERMEDIN; HYDRAZINONICOTINAMIDE TYROSYLGLUTAMYLARGINYLLYSYLPHENYLALANYLTRYPTOPHYLHISTIDYLGLYCYLARGINYLHISTIDINE; LUTETIUM 177; NICOTINAMIDE DERIVATIVE; RHENIUM 188;

CANCER RADIOTHERAPY; DRUG RESEARCH; DRUG STRUCTURE; DRUG TARGETING; HUMAN; MELANOMA; NONHUMAN; RADIOISOTOPE THERAPY; REVIEW;

ANIMALS; CELL LINE, TUMOR; HUMANS; MELANINS; MELANOMA; MELANOMA, EXPERIMENTAL; MICE; PEPTIDES; RADIOISOTOPES; RECEPTOR, MELANOCORTIN, TYPE 1; TREATMENT OUTCOME; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 48949095565     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2008.02.006     Document Type: Review

References (94)

1. Jemal A., Siegel R., Ward E., et al. Cancer Statistics 2008. CA Cancer J Clin 58 (2008) 71-96
2. Marghood A.A., Slade J., Salopek T.G., Kopf A.W., Bart R.S., and Rigel D.S. Basal cell and squamous cell carcinomas are important risk factors for cutaneous malignant melanoma. Cancer 75 (1995) 707-714
3. Dennis L.K. Analysis of the melanoma epidemic, both apparent and real: data from 1973 through 1994 surveillance, epidemiology, and end results program registry. Arch Dermatol 135 (1999) 275-280
4. Balch C.M., Soong S.J., Atkins M.B., et al. An evidence-based staging system for cutaneous melanoma. CA Cancer J Clin 54 (2004) 131-149
5. Del Prete S.A., Maurer L.H., O'Donnell J., Forcier R.J., and LeMarbre P. Combination chemotherapy with cisplatin, carmustine, dacarbazine, and tamoxifen in metastatic melanoma. Cancer Treat Rep 68 (1984) 1403-1405
6. Chapman P.B., Einhorn L.H., Meyers M.L., et al. Phase III multicenter randomized trial of the Dartmouth regimen versus Dacarbazine in patients with metastatic melanoma. J Clin Oncol 17 (1999) 2745-2751
7. Balch C.M., Soong S.J., Gershenwald J.E., et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American joint committee on cancer melanoma staging system. J Clin Oncol 19 (2001) 3622-3634
8. Anderson C.M., and Buzaid A.C. Systematic treatments for advanced cutaneous melanoma. Oncology 9 (1995) 1149-1158
9. Heppeler A., Froidevaux S., Eberle A.N., and Maecke H.R. Receptor targeting for tumor localization and therapy with radiopeptides. Curr Med Chem 7 (2000) 971-994
10. Volkert W.A., Goeckeler W.F., Ehrhardt G.J., and Ketring A.R. Therapeutic radionuclides: production and decay property consideration. J Nucl Med 32 (1991) 174-185
11. Otte A., Jermann E., Behe M., et al. A powerful new tool for receptor-mediated radionuclide therapy. Eur J Nucl Med 24 (1997) 792-795
12. Otte A., Mueller-Brand J., Dellas S., et al. Yttrium-90-labelled somatostatin-analogue for cancer treatment. Lancet 351 (1998) 417-418
13. Zamora P.O., Bender H., Gulhke S., et al. Pre-clinical experience with Re-188-RC-160, a radiolabeled somatostatin analog for use in peptide-targeted radiotherapy. Anticancer Res 17 (1997) 1803-1808
14. 3]octreotate for somatostatin receptor-targeted radionuclide therapy. Int J Cancer 92 (2001) 628-633
15. Freitas J.E., Gross M.D., Ripley S., and Shapiro B. Radionuclide diagnosis and therapy of thyroid cancer: current status report. Semin Nucl Med 15 (1985) 106-131
16. Hoefnagel C.A. Radionuclide therapy revisited. Eur J Nucl Med 18 (1991) 408-431
17. Tatro J.B., Wen Z., Entwistle M.L., et al. Interaction on an α-melanocyte stimulating hormone-diptheria toxin fusion protein with melanotropin receptors in human metastases. Cancer Res 52 (1992) 2545-2548
18. Froidevaux S., Calame-Christe M., Tanner H., Sumanovski L., and Eberle A.N. A novel DOTA-α-melanocyte-stimulating hormone analog for metastatic melanoma diagnosis. J Nucl Med 43 (2002) 1699-1706
19. Eberle A.N., and Froidevaux S. Radiolabeled α-melanocyte-stimulating hormone analogs for receptor-mediated targeting of melanoma: from tritium to indium. J Mol Recognit 16 (2003) 248-254
20. Miao Y., Whitener D., Feng W., Owen N.K., Chen J.Q., and Quinn T.P. Evaluation of the human melanoma targeting properties of radiolabeled α-melanocyte stimulating hormone peptide analogues. Bioconjug Chem 14 (2003) 1177-1184
21. Miao Y., and Quinn T.P. Alpha-melanocyte stimulating hormone peptide-targeted melanoma imaging. Front Biosci 12 (2007) 4514-4524
22. Hearing V. The melanosome: the perfect model for cellular responses to the environment. Pigment Cell Res 13 Suppl. 8 (2000) 23-34
23. Ings R.M. The melanin binding of drugs and its implications. Drug Metab Rev 15 (1984) 1183-1212
24. Fogarty R.V., and Tobin J.M. Fungal melanins and their interactions with metals. Enzyme Microb Technol 19 (1996) 311-317
25. Dadachova E., Nosanchuk J.D., Shi L., et al. Dead cell in melanoma tumors provide abundant antigen or targeted delivery of ionizing radiation by mAb to melanin. Proc Natl Acad Sci 101 (2004) 14865-14870
26. 3]Octreotate in patients with paraganglioma, meningioma, small cell lung carcinoma, and melanoma. J Nucl Med 47 (2006) 1599-1606
27. Giblin M.F., Jurisson S.S., and Quinn T.P. Synthesis and characterization of rhenium-complexed alpha-melanotropin analogs. Bioconjug Chem 8 (1997) 347-353
28. Giblin M.F., Wang N., Hoffman T.J., Jurisson S.S., and Quinn T.P. Design and characterization of alpha-melanotropin peptide analogs cyclized through rhenium metal coordination. Proc Natl Acad Sci USA 95 (1998) 12814-12818
29. 188Re-labeled linear alpha-melanocyte stimulating hormone analogs for specific melanoma targeting. Nucl Med Biol 26 (1999) 687-693
30. 188Re labeled alpha-melanocyte stimulating hormone peptide analogs for melanoma therapy. Int J Cancer 101 (2002) 480-487
31. 188Re labeled α-melanocyte stimulating hormone peptide analogue in murine and human melanoma-bearing mouse models. J Nucl Med 46 (2005) 121-129
32. Dadachova E., Model T., Schweitzer A.D., et al. Radiolabeled melanin-binding peptides are safe and effective in treatment of human pigmented melanoma in a mouse model of disease. Cancer Biother Radiopharm 21 (2006) 117-129
33. 177Lu labeled alpha-melanocyte stimulating hormone peptide analogues in a murine melanoma model. Nucl Med Biol 32 (2005) 485-493
34. 177Lu labeled DOTA conjugated α-melanocyte stimulating hormone peptide in a murine melanoma-bearing mouse model. Cancer Biother Radiopharm 22 (2007) 333-341
35. 11), a cyclic peptide analogue of α-MSH. J Med Chem 48 (2005) 2985-2992
36. 64Cu-labled rhenium-cyclized α-MSH peptide analogs using a cross-bridged cyclam chelator. J Nucl Med 48 (2007) 64-72
37. 64Cu-labeled alpha-melanocyte-stimulating hormone analog for MicroPET imaging of melanocortin 1 receptor expression. Bioconjug Chem 18 (2007) 765-772
38. Miao Y., Hylarides M., Fisher D.R., et al. Melanoma therapy via peptide-targeted alpha-radiation. Clin Cancer Res 11 (2005) 5616-5621
39. 2)-tyrosine2-α-melanotropin, and of related peptides. Helv Chim Acta 62 (1979) 2460-2483
40. Eberle A.N., Jäggin Verin V., Solca F., et al. Biologically active monoidoinated α-MSH derivatives for receptor binding studies using human melanoma cells. J Recept Res 11 (1991) 311-322
41. John C.S., Bowen W.D., Saga T., et al. A malignant melanoma imaging agent: synthesis, characterization, in vitro binding and biodistribution of iodine-125-(2-piperidinylaminoethyl)4-iodobenzamide. J Nucl Med 34 (1993) 2169-2175
42. Garg P.K., Alston K.L., Welsh P.C., and Zalutsky M.R. Enhanced binding and inertness to dehalogenation of α-melanotropic peptides labeled using N-succinimidyl 3-iodobenzoate. Bioconjug Chem 7 (1996) 233-239
43. Cheng Z., Chen J., Quinn T.P., and Jurisson S.S. Radioiodination of rhenium cyclized alpha-melanocyte-stimulating hormone resulting in enhanced radioactivity localization and retention in melanoma. Cancer Res 64 (2004) 1411-1418
44. 3}octreotide, a promising somatostatin analogue for radionuclide therapy. Eur J Nucl Med 24 (1997) 368-371
45. 111In-labeled somatostatin analogues for tumor scintigraphy and radionuclide therapy. Cancer Res 58 (1998) 437-441
46. 0]octreotide: the Rotterdam experience. Semin Nucl Med 32 (2002) 110-122
47. Anthony L.B., Woltering E.A., Espanan G.D., Cronin M.D., Maloney T.J., and McCarthy K.E. Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies. Semin Nucl Med 32 (2002) 123-132
48. Ginj M., Hinni K., Tshumi S., Schulz S., and Maecke H. Trifunctional somatostatin-based derivatives designed for targeted radiotherapy using auger electron emitters. J Nucl Med 46 (2005) 2097-2103
49. 111In-DOTA-rhenium cyclized α-MSH analog: a novel cyclic-peptide analog with improved tumor targeting properties. J Nucl Med 42 (2001) 1847-1855
50. 111In labeled DOTA conjugated rhenium cyclized α-MSH analogs. J Med Chem 45 (2002) 3048-3056
51. Froidevaux S., Calame-Christe M., Tanner H., Sumanovski L., and Eberle A.N. A novel DOTA-alpha-melanocyte-stimulating hormone analog for metastatic melanoma diagnosis. J Nucl Med 43 (2002) 1699-1706
52. Froidevaux S., Calame-Christe M., Schuhmacher J., et al. A gallium-labeled DOTA-alpha-melanocyte-stimulating hormone analog for PET imaging of melanoma metastases. J Nucl Med 45 (2004) 116-123
53. Froidevaux S., and Eberle A.N. DOTA alpha-melanocyte-stimulating hormone analogues for imaging metastatic melanoma lesions. Ann N Y Acad Sci 994 (2003) 378-383
54. 111In-labeled alpha-melanocyte stimulation hormone peptides as imaging probes for primary and pulmonary metastatic melanoma detection. J Nucl Med 48 (2007) 73-80
55. Garg P.K., Alston K.L., Welsh P.C., and Zalutsky M.R. Enhanced binding and inertness to dehalogenation of α-melanotropic peptides labeled using N-succinimidyl-3-iodobenzoate. Bioconjug Chem 7 (1996) 233-239
56. 7]-alpha-MSH, an alpha-melanocyte stimulating hormone analogue. Nucl Med Biol 24 (1997) 171-178
57. 18F-labeled α-melanocyte-stimulating hormone analog. J Nucl Med 48 (2007) 987-994
58. Schubiger P.A., Alberto R., and Smith A. Vehicles, chelators and radionuclides: choosing the "building blocks" of an effective therapeutic radioimmunoconjugate. Bioconjug Chem 7 (1996) 165-179
59. McDevitt M.R., Ma D., Lai L.T., et al. Tumor therapy with targeted atomic nanogenerators. Science 294 (2001) 1537-1540
60. 3]-octreotide radionuclide therapy in a transplantable rate tumor model is dependent on tumor size. J Nucl Med 42 (2001) 1841-1846
61. De Jong M., Valkema R., Jamar F., et al. Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings. Semin Nucl Med 32 (2002) 133-140
62. Teuissen J.J.M., Kwekkeboom D.J., De Jong M., Esser J.P., Valkema R., and Krenning E.P. Peptide receptor radionuclide therapy. Best Pract Res Clin Gastroenterol 19 (2005) 595-616
63. McDevitt M.R., Sgouros G., Finn R.D., et al. Radioimmunotherapy with alpha-emitting nuclides. Eur J Nucl Med 25 (1998) 1341-1351
64. Zalutsky M.R., and Bigner D. Radioimmunotherapy with alpha-particle emitting radioimmunoconjugates. Acta Oncol 35 (1996) 373-379
65. Larsen R.H., Akabani G., Welsh P., and Zalutsky M.R. The cytotoxicity and microdosimetry of Astatine-211-labeled chimeric monoclonal antibodies in human glioma and melanoma cells. Radiat Res 149 (1998) 155-162
66. Behr T., Behe M., Lohr M., et al. Therapeutic advantages of Auger electron-over beta-emitting radiometals or radioiodine when conjugated to internalizing antibodies. Eur J Nucl Med 27 (2000) 753-765
67. Sawyer T.K., Staples D.J., Catrucci A.M.L., et al. Alpha-melanocyte stimulating hormone message and inhibitory sequences: comparative structure activity studies on melanocytes. Peptides 11 (1990) 351-357
68. Cone R.D., Lu D., Koppula S., et al. The melanocortin receptors: agonists, antagonists, and the hormonal control of pigmentation. Recent Prog Horm Res 51 (1996) 287-317
69. 7]-α-MSH in B16 melanoma cells. Int J Biochem Cell Biol 28 (1996) 1223-1232
70. Nosanchuk J.D., Valadon P., Feldmesser M., and Casadevall A. Melanization of cryptococcus neoforms in murine infection. Mol Cell Biol 19 (1999) 745-750
71. 213Bi and their decay chain related radionuclides, for therapy applications. Chem Rev 101 (2001) 2019-2036
72. Leichner P.K. Radiation dosimetry of monoclonal antibodies: practical considerations. In: Henkin R.E., Boles M.A., Dillehay G.L., et al. (Eds). Nuclear medicine (1996), St. Louis, Mosby 558-562
73. Acher R.N., Friedman A.M., and Hines J.J. An improved generator for the production of Pb-212 and Bi-212 from Ra-224. Appl Radiat Isot 39 (1988) 283-286
74. Mirzadeh S., Kumar K., and Gansow O.A. The chemical fate of Bi-212-DOTA formed by β-decay of Pb(DOTA). Radiochim Acta 60 (1993) 1-10
75. Jones S.B., Tiffany L.J., Garmestani K., Gansow O.A., and Kozak R.W. Evaluation of dithiol chelating agents as potential adjuvants for anti-IL-2 receptor lead or bismuth a radioimmunotherapy. Nucl Med Biol 23 (1996) 105-113
76. 99mTechnetium-labeled cyclic α-melanocyte stimulating hormone peptide analogues. Cancer Res 60 (2000) 5649-5658
77. Joiner M.C., Marples B., Lambin P., Short S.C., and Turesson I. Low-dose hypersensitivity: current status and possible mechanisms. Int J Radiat Oncol Biol Phys 49 (2001) 379-389
78. 18F-2-deoxy-2-fluor-d-Glucose. Cancer Res 65 (2005) 698-702
79. 90Y-DOTATOC. Eur J Nucl Med 26 (1999) 887-896
80. Otte A., Heppeler A., Behe M., et al. Yttrium-90 DOTATOC: first clinical trial. Eur J Nucl Med 26 (1999) 1439-1447
81. Moll S., Nickeleit V., Mueller-Brand J., Brunner F.P., Maecke H.R., and Mihatsch M.J. A new case of renal thrombotic microangiopathy: yttrium 90-DOTATOC internal radiotherapy. Am J Kidney Dis 37 (2001) 847-851
82. Boerman O., Oyen W.J., and Corstens F.H. Between the Scylla and Charybdis of peptide radionuclide therapy: hitting the tumor and saving the kidney. Eur J Nucl Med 28 (2001) 1447-1449
83. Behr T.M., Béhé M., Kuge G., Gotthardt M., Schipper M.L., and Gratz S. Nephrotoxicity versus anti-tumour efficacy in radiopeptide therapy: facts and myths about the Scylla and Charybdis. Eur J Nucl Med 29 (2002) 277-279
84. Jaggi J.S., Kappel B.J., McDevitt M.R., et al. Efforts to control the errant products of targeted in vivo generator. Cancer Res 65 (2005) 4888-4895
85. Gotthardt M., van Eerd-Vismale J., Oyen W.J., et al. Indication for different mechanisms of kidney uptake of radiolabeled peptides. J Nucl Med 48 (2007) 596-601
86. 203Pb-labeled alpha-melanocyte stimulating hormone peptide as an imaging probe for melanoma detection. J Nucl Med 49 (2008) 823-829
87. 99mTc-MIBI scintigraphy. J Nucl Med 44 (2003) 1561-1565
88. Acland K.M., Healy C., Calonje E., et al. Comparison of positron emission tomography scanning and sentinel node biopsy in the detection of micrometastases of primary cutaneous malignant melanoma. J Clin Oncol 19 (2001) 2674-2678
89. 18F-fluorodeoxyglucose positron emission tomography in melanoma patients. Cancer 91 (2001) 1530-1542
90. Krug B., Dietlein M., Groth W., et al. Fluor-18-fluorodeoxyglucose positron emission tomography (FDG-PET) in malignant melanoma. Acta Radiol 41 (2000) 446-452
91. Wagner J.D., Schauwecker D., Davidson D., et al. Inefficacy of F-18 fluorodeoxy-d-glucose-positron emission tomography scans for initial evaluation in early-stage cutaneous melanoma. Cancer 104 (2005) 570-579
92. 18F-FDG PET more accurate than standard diagnostic procedures in the detection of suspected recurrent melanoma. J Nucl Med 45 (2003) 1323-1327
93. McDevitt M.R., Ma D., Lai L.T., et al. Tumor therapy with targeted atomic nanogenerators. Science 249 (2001) 1537-1540
94. 213Bi-HuM195 (anti-CD33) in patients with leukemia. J Nucl Med 40 (1999) 1935-1946